Print

Lay Description

Purpose/Objectives: With REMD’s glucagon receptor antagonist, we propose to provide a comprehensive examination of the effect of elevated plasma glucagon concentrations in T2D patients on:  (i) glucose tolerance; (ii) insulin sensitivity in liver, muscle, and adipocytes; (iii) beta cell function; (iv) adipocyte inflammation.

Clinical Relevance: Glucagon is a hormone normally produced by pancreas which is usually elevated in patients with diabetes and we want to see if we block the effect of glucagon with the drug called REMD-477 we can improve glucose levels.

Category

  • Diabetes
IRB Number
20210463HU
NCT Number
ct.gov registration not required
Open to Enrollment
Yes

Eligibility

Eligible Ages
18-70
Eligible Genders
All
Accepts Healthy Volunteers

Inclusion Criteria

Good general health determined by medical  history, physical exam, and routine blood chemistries; BMI = 25-40 kg/m2; HbA1c 7.5-10.0%; Type 2 Diabetics who are drug naïve or treated with metformin, sulfonylureas, SGLT-2 inhibitors or any combination thereof.

Exclusion Criteria

Type 1 diabetes, Subjects treated with GLP-1 RAs or insulin

Study Design

Arm Groups

Study Contact

Regulatory Point of Contact
Ralph DeFronzo
(210) 567-6691
defronzo@uthscsa.edu

Regulatory Point of Contact
Andrea Hansis-diarte
+1 (210) 617-5300
hansisdiarte@uthscsa.edu

Local Recruitment Point of Contact
Andrea Hansis-diarte
+1 (210) 617-5300
hansisdiarte@uthscsa.edu

Overall Recruitment Point of Contact
Ralph DeFronzo
(210) 567-6691
defronzo@uthscsa.edu

Principal Investigator
Ralph DeFronzo